Finding better drugs, faster.
Finding better drugs, faster.
Finding better drugs, faster.
By combining the power of AI with the depth of 3D cell biology, we are pushing the boundaries of oncological drug discovery. 
By combining the power of AI with the depth of 3D cell biology, we are pushing the boundaries of oncological drug discovery. 
By combining the power of AI with the depth of 3D cell biology, we are pushing the boundaries of oncological drug discovery. 
New approach to drug discovery.
New approach to drug discovery.
At Sentinal4D, we believe patients battling cancer, neurodegenerative diseases, and chronic inflammatory syndromes deserve personalized therapeutics. We are deploying a biology-first, holistic approach with focus on phenotypic-based drug discovery.
By harnessing AI-powered 3D cell imaging, we are transforming drug discovery and development, accelerating the journey of groundbreaking treatments from lab to clinic.
The Difference.
The Difference.
By integrating deep learning with 3D and 4D morphological profiling, Sentinal4D provides a more holistic view of cellular biology, enabling sensitive phenotypic analysis.
This unique combination of technology and biological expertise sets us apart, offering insights that drive drug discovery, improve patient outcomes, and transform the future of personalised medicine.
Melanoma
Breast cancer
Pancreatic
Colorectal
Neuroblastoma
Melanoma
Breast cancer
Pancreatic
Colorectal
Neuroblastoma
Melanoma
Breast cancer
Pancreatic
Colorectal
Neuroblastoma
The Team.
The Team.
Building on 20 years of experience in cutting edge cell biology research, we are world leaders in the cell omics space.
Georgia Mitsi
CEO & Co-founder
Innovation expert
Georgia Mitsi
CEO & Co-founder
Innovation expert
Georgia Mitsi
CEO & Co-founder
Innovation expert
Chris Bakal
CSO & Co-founder
Professor, Institute of Cancer research, Harvard Medical School and MIT
Chris Bakal
CSO & Co-founder
Professor, Institute of Cancer research, Harvard Medical School and MIT
Chris Bakal
CSO & Co-founder
Professor, Institute of Cancer research, Harvard Medical School and MIT
Matt DeVries
CTO & Co-founder
A.I. expert
Matt DeVries
CTO & Co-founder
A.I. expert
Matt DeVries
CTO & Co-founder
A.I. expert
Science behind the Sentinel4D technology
Science behind the Sentinel4D technology
By
Chris Bakal
Does More Data Mean Better AI in Drug Discovery? Rethinking the Foundation.
Does More Data Mean Better AI in Drug Discovery? Rethinking the Foundation.
AI is transforming drug discovery, but the quality of its data is often overlooked, leading to biased predictions and missed opportunities.
Read More
Contact Us
If you would like to learn more about Sentinal4D please fill the form.
info@sentinal4d.com.

Flat 3702 55 Upper Ground,

London, United Kingdom, SE1 9HE

.

©2024 by SENTINAL4D
Contact Us
If you would like to learn more about Sentinal4D please fill the form.
info@sentinal4d.com.

Flat 3702 55 Upper Ground,

London, United Kingdom, SE1 9HE

©2024 by SENTINAL4D
Contact Us
If you would like to learn more about Sentinal4D please fill the form.
info@sentinal4d.com.

Flat 3702 55 Upper Ground,

London, United Kingdom, SE1 9HE

.

©2024 by SENTINAL4D